Today Ortho-Clinical Diagnostics, Inc. (OCD) unveiled its newly expanded
executive leadership team following the acquisition of the company by
The Carlyle Group (NASDAQ: CG) from Johnson & Johnson. In his first act
as OCD Chairman and Chief Executive Officer, Dr. Martin D. Madaus
announced key appointments in finance, operations, legal and commercial
to advance strategic sectors of the In Vitro Diagnostics (IVD) business.
"We have recruited top industry talent, recognized for their global
diagnostics expertise, to build a revitalized, stand-alone company,"
said Dr. Madaus. "Under their leadership, OCD will be positioned to
grow, enhance its industry-leading medical diagnostics products and
services, and innovate with new, diagnostic solutions through targeted
In February, The Carlyle Group announced that Dr. Madaus would lead OCD
after the acquisition. Dr. Madaus has leveraged his business acumen and
more than 25 years of experience in the diagnostics and life sciences
industries to lay the groundwork for an independent OCD. Dr. Madaus and
OCD will have a central focus on ensuring a seamless transition for
customers. Today, the company announced the following appointments:
Mr. Socarras has strong commercial and general management experience in
diagnostics in theU.S., Latin America and Europe. Prior to joining
Ortho Clinical Diagnostics, Mr. Socarras was a senior vice president and
CEO of healthcare in South West Europe at Siemens Healthcare. He also
served as their vice president and region CEO of Latin America.
Mr. Yates has extensive senior leadership experience delivering
significant commercial and business successes in diagnostics and life
sciences. He joins Ortho Clinical Diagnostics from EMD Millipore, where
he served as president and CEO, leading the company through a period of
outstanding growth. Prior to EMD Millipore, Mr. Yates was the head of
life sciences, diagnostics business development and U.S. operations at
Mr. Capello has demonstrated a consistent record of improving the
operational and financial health of global organizations across multiple
industries. He was most recently Executive Vice President and Chief
Financial Officer at Boston Scientific and has more than 29 years of
experience in various roles in which he drove operational improvement
and implemented strategies to drive value.
Mr. Schlesinger has extensive experience in corporate practice and M&A,
and provided in-house counsel for a variety of venture-backed firms. As
a former partner and corporate lawyer at Latham & Watkins, LLP, he has
more than 25 years of experience representing numerous companies in a
variety of business transactions including, acquisitions, sales,
mergers, joint ventures and divestitures.
About Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc. delivers high-quality in vitro
diagnostic products that give healthcare professionals around the world
the knowledge they need to make better treatment decisions sooner. The
company serves the global transfusion medicine community with donor
screening and blood typing products to help ensure every patient
receives blood that is safe, the right type and the right unit.
Ortho-Clinical Diagnostics, Inc. also brings sophisticated information
management, testing technologies and automation and interpretation tools
to clinical laboratories worldwide to help them run more efficiently and
improve patient care. For more information, visit www.orthoclinical.com.
[ Back To NFVZone's Homepage ]